Login / Signup

Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study.

Claudio Maurizio PacellaGianluigi PatelliGennaro IapiccaGuglielmo ManentiTommaso PerrettaColleen P RyanRenato EspositoGiovanni Mauri
Published in: Prostate cancer and prostatic diseases (2019)
SoracteLite™ TPLA allows significant improvement of IPSS, Qol, Qmax, PVR, and reduction of prostatic volume at 6 and 12 months.
Keyphrases
  • benign prostatic hyperplasia
  • lower urinary tract symptoms
  • radiofrequency ablation
  • minimally invasive
  • prostate cancer
  • ultrasound guided
  • replacement therapy
  • catheter ablation